Search Clinical Trials in the European Union

Duration
Visits
Efficacy phase (II)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
981-1000 of 1,738 trials

Metastatic Renal Cell Carcinoma: Temferon Gene Therapy

We are testing a new gene therapy using modified stem cells for patients with metastatic renal cell carcinoma. The study aims to evaluate the safety and biological response to a single dose of Temferon.

Metastatic Kidney Cancer1-2 yearsSafety phase (I)Efficacy phase (II)16-20 visitsNo PlaceboInvestigational MedicinesHematologyOncology

Bladder Cancer: EG-70 Treatment Study

We are testing a new treatment called EG-70 for patients with bladder cancer that hasn't responded to standard therapy. The study aims to see if it can help improve outcomes and quality of life for these patients.

Non-muscle invasive bladder cancer>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesOncologyUrology

Episodic Migraine: MEDI0618 Treatment Study

We are investigating whether the new medication MEDI0618 can help reduce the number of migraine days for adults with episodic migraines compared to a placebo. This study aims to assess its safety and effectiveness.

Migraine6-12 monthsEfficacy phase (II)Investigational MedicinesNeurology

Severe Alcohol-Associated Hepatitis: INT-787 Study

We are testing a new medication, INT-787, for individuals with severe alcohol-associated hepatitis. The goal is to see if it can help slow down the progression of this serious liver disease.

Alcoholic Hepatitis3-6 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesPartially RemoteHepatologyInternal Medicine

Fecal Microbiota Transplantation for Blood Cancer Stem Cell Transplant Patients

We are studying whether fecal microbiota transplantation can help prevent complications after stem cell transplants in patients with blood cancers. This trial will assess its effects on survival and quality of life.

Patients Post Allogeneic Stem Cell Transplant>2 yearsEfficacy phase (II)Investigational MedicinesHematologyOncology

B-Cell Non-Hodgkin Lymphoma: BI-1206 Treatment Study

We are studying a new monoclonal antibody combined with rituximab, with or without acalabrutinib, for patients with relapsed or refractory B-cell non-Hodgkin lymphoma. The goal is to assess safety and how well it may work in reducing cancer cells.

Indolent B-Cell Non-Hodgkin Lymphoma3-6 monthsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesOncology

Esophageal Adenocarcinoma: The PRESTO Trial

We are studying a combination of durvalumab and chemoradiation to see if it can help preserve the esophagus in patients with early-stage cancer. This trial aims to avoid surgery and assess treatment effectiveness and safety.

Esophageal Cancer>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesOncology

Metastatic Colorectal Cancer: Telisotuzumab Adizutecan Study

We are investigating a new treatment combination for people with metastatic colorectal cancer to see if it works better and is safer than current standard treatments.

Metastatic Colorectal Cancer≤3 monthsEfficacy phase (II)No PlaceboInvestigational MedicinesOncology

Advanced Gastric Cancer: New Drug Combinations

We are studying whether a new combination of trifluridine/tipiracil and oxaliplatin, with or without nivolumab, is more effective than standard treatment for patients with advanced gastric or esophageal cancer. The goal is to improve survival and quality of life for those with HER2 negative cancer.

HER2 Negative Gastric CancerEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesGastroenterologyOncology

Prednisone for Idiosyncratic Hepatotoxicity

We are studying whether prednisone can help reduce liver damage in patients with idiosyncratic hepatotoxicity. The trial will also assess its safety and impact on quality of life compared to a placebo.

Liver Toxicity>2 yearsEfficacy phase (II)6-10 visitsInvestigational MedicinesHepatologyInternal Medicine

Targeted Therapies for Moderate to Severe Crohn’s Disease

We are studying new targeted treatments for adults with moderate to severe Crohn’s disease. The goal is to evaluate their safety and effectiveness in managing this condition.

Crohn's Disease3-6 monthsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteGastroenterologyInternal Medicine

Mucosal Melanoma: Anti-PD1 Immunotherapy Study

We are investigating whether a new treatment combining anti-PD1 therapy with surgery improves disease-free survival in patients with resectable mucosal melanoma. This study aims to evaluate the effectiveness and safety of this approach.

Melanoma>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesCost ReimbursementPartially RemoteDermatologyOncology

NY-ESO-1 T-Cells for Synovial Sarcoma and Liposarcoma

We are studying genetically engineered T cells in patients with synovial sarcoma and myxoid/round cell liposarcoma. The goal is to see if this treatment is effective and safe for those with specific tumor markers.

Myxoid and Round Cell LiposarcomaSynovial SarcomaEfficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteOncology

Psychosis in Alzheimer's: ITI-1284 Study

We are evaluating a new medication, ITI-1284, for treating psychosis in patients with Alzheimer's disease. The study aims to see if it is more effective than a placebo in improving symptoms.

Psychosis associated with Alzheimer’s Disease3-6 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesCost ReimbursementPsychiatry

Advanced Solid Tumors: PM534 Treatment Study

We are testing a new drug called PM534 in patients with advanced solid tumors. The goal is to learn more about its safety and how it may work in treating this condition.

Advanced Solid Tumors>2 yearsSafety phase (I)Efficacy phase (II)Oncology

Tuberous Sclerosis Complex: Vigabatrin vs. Rapamycin

We are comparing the safety and effectiveness of two medications, vigabatrin and rapamycin, in preventing symptoms of Tuberous Sclerosis Complex in infants. This study aims to understand how these treatments affect epilepsy severity and overall quality of life.

Tuberous Sclerosis Complex>2 yearsEfficacy phase (II)Confirmation phase (III)>20 visitsPost-Trial Drug AccessStandard MedicinesPartially RemoteNeurologyPediatrics

HPV Vaccination After Cervical Lesion Treatment

We are studying whether a secondary HPV vaccination helps women over 45 who have been treated for high-grade cervical lesions achieve HPV-negative status and reduce the risk of recurrence or cancer.

High-Grade Cervical Intraepithelial Lesions>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesGynecology and ObstetricsInfectious Diseases

Acute Myeloid Leukemia: Sulfasalazine with Chemotherapy

We are studying the addition of sulfasalazine to standard chemotherapy for elderly patients with newly diagnosed acute myeloid leukemia. The goal is to evaluate safety and effectiveness compared to existing treatments.

Acute Myeloid Leukemia>2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesHematologyOncology

MEN1703 for Aggressive B-cell Non-Hodgkin Lymphoma

We are studying the safety and effectiveness of MEN1703 alone and with glofitamab in patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma. This research aims to find better treatment options for this challenging cancer.

Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma6-12 monthsEfficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementOncology

Head and Neck Cancer: New Drug Combinations

We are studying a new combination of drugs for patients with recurrent or metastatic head and neck cancer. The goal is to see if this combination works better than the current treatment options.

Recurrent Head and Neck Squamous Cell CarcinomaEfficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteOncology